Dual-stabilized selenium nanoparticles with chitosan and SS31 peptide: Resolving instability for enhancing ROS elimination, suppressing inflammation, and combating bacterial infections.

Ming P, Wei Y, Zhu Y, Li K, Zhu W, Qiu J

Colloids and surfaces. B, Biointerfaces30 Apr 2025Cited by 6 (Europe PMC)

PMID40318392DOI10.1016/j.colsurfb.2025.114749PepBankPUB-40318392

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In zebrafish with copper sulfate-induced inflammation, CS/SS31-SeNPs pretreatment reduced neutrophil recruitment by 38.07 %, more than bare SeNPs.
In plain wordsIn zebrafish with induced inflammation, a nanoparticle containing SS31 reduced immune cell recruitment more than the nanoparticle without it.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseNeutrophil recruitment
Study
zebrafishn: not reported in source
copper sulfate-induced inflammation
Comparator
Bare SeNPs
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Neutrophil recruitment reduction
38.07%
CS/SS31-SeNPs
Source sentences
Summary
In a copper sulfate-induced zebrafish inflammation model, CS/SS31-SeNPs pretreatment reduced neutrophil and macrophage recruitment by 38.07 % and 43.56 %, respectively, outperforming bare SeNPs.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4031839203
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In zebrafish with copper sulfate-induced inflammation, CS/SS31-SeNPs pretreatment reduced macrophage recruitment by 43.56 %, more than bare SeNPs.
In plain wordsIn zebrafish with induced inflammation, a nanoparticle containing SS31 reduced immune cell recruitment more than the nanoparticle without it.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMacrophage recruitment
Study
zebrafishn: not reported in source
copper sulfate-induced inflammation
Comparator
Bare SeNPs
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Macrophage recruitment reduction
43.56%
CS/SS31-SeNPs
Source sentences
Summary
In a copper sulfate-induced zebrafish inflammation model, CS/SS31-SeNPs pretreatment reduced neutrophil and macrophage recruitment by 38.07 % and 43.56 %, respectively, outperforming bare SeNPs.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4031839204
03LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
The CS/SS31-SeNPs nanocomposite showed enhanced ROS scavenging efficiency in vitro and in vivo.
In plain wordsIn lab tests and animals, a nanoparticle containing SS31 cleared reactive oxygen species better.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseROS scavenging in vitro and in vivo
Study
n: not reported in source
CS/SS31-SeNPs nanocomposite
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The nanocomposites demonstrated enhanced reactive oxygen species (ROS) scavenging efficiency in vitro and in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4031839202
04LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Activity measurement
CS/SS31-SeNPs showed superior antibacterial activity against Staphylococcus aureus, with near-complete growth inhibition at 64 μM.
In plain wordsIn lab tests, a nanoparticle containing SS31 almost fully stopped Staphylococcus aureus growth at 64 μM.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseAntibacterial activity against S. aureus
Study
Staphylococcus aureusn: not reported in source
CS/SS31-SeNPs nanocomposite
Outcome group
Infection and antimicrobial activity · Infection
Measurements
Growth inhibition concentration
64 μM
S. aureus
Source sentences
Summary
Furthermore, CS/SS31-SeNPs exhibited superior antibacterial activity against Staphylococcus aureus, achieving near-complete growth inhibition at 64 μM.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4031839205
05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Other
The CS/SS31-SeNPs nanocomposite was spherical (82 nm, +48 mV zeta potential) and showed no aggregation over 90 days.
In plain wordsIn lab tests, a nanoparticle made with SS31, chitosan and selenium was stable for 90 days.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableNanocomposite size, charge and stability
Study
n: not reported in source
CS/SS31-SeNPs nanocomposite
Outcome group
Receptor activity and mechanism · Pharmacology
Measurements
Diameter
82 nm
CS/SS31-SeNPs
Zeta potential
48 mV
CS/SS31-SeNPs
Source sentences
Summary
The optimized CS/SS31-SeNPs exhibited a uniform spherical structure (82 nm diameter, +48 mV zeta potential) and exceptional stability (no aggregation over 90 days
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4031839201
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Mechanism
Mechanistic studies indicated that the antibacterial action of CS/SS31-SeNPs stems from targeting the MraY enzyme in peptidoglycan synthesis.
In plain wordsIn lab tests, a nanoparticle containing SS31 appeared to kill bacteria by acting on an enzyme needed for cell wall building.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableAntibacterial target MraY
Study
n: not reported in source
CS/SS31-SeNPs nanocomposite
Outcome group
Receptor activity and mechanism · Infection
Source sentences
Summary
Mechanistic studies revealed that the antibacterial action stems from targeting the conserved MraY enzyme in peptidoglycan synthesis.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4031839206
07Computer modelNot a test of Elamipretide (SS-31) aloneIn silicoMechanism
Molecular docking indicated stable binding of CS/SS31-SeNPs to the uracil pocket of MraY and adjacent sites.
In plain wordsIn a computer model, a nanoparticle containing SS31 bound stably to a bacterial enzyme.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableDocking binding energy to MraY
Study
n: not reported in source
CS/SS31-SeNPs nanocomposite
Outcome group
Receptor activity and mechanism · Pharmacology
Measurements
Docking binding energy
−15.6 kcal/mol
MraY uracil pocket
Source sentences
Summary
Molecular docking indicated stable binding (-15.6 kcal/mol) of CS/SS31-SeNPs to MraY's uracil pocket and adjacent sites-a mechanism distinct from conventional antibiotics, suggesting broad-spectrum potential.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4031839207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.